The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Recruiting · NCT06620809 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Phase 1 | 2026-09-21 | NCT06620809 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| iRegene Therapeutics Co., Ltd. | 8 |
| Tongji Hospital | 276 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | China | 9 |